Global Gastrointestinal Therapeutics Strategic Business Report 2022: Market to Reach $84.4 Billion by 2027 – Crohn’s Disease is Expected to Account for $16.3 Billion – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Gastrointestinal Therapeutics: Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.

Global Gastrointestinal Therapeutics Market to Reach $84.4 Billion by 2027

The global market for Gastrointestinal Therapeutics estimated at US$61.2 Billion in the year 2020, is projected to reach a revised size of US$84.4 Billion by 2027, growing at a CAGR of 4.7% over the analysis period 2020-2027.

Crohn`s Disease, one of the segments analyzed in the report, is projected to record a 4.6% CAGR and reach US$16.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ulcerative Colitis segment is readjusted to a revised 4.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $16.5 Billion, While China is Forecast to Grow at 7.5% CAGR

The Gastrointestinal Therapeutics market in the U.S. is estimated at US$16.5 Billion in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$17.5 Billion by the year 2027 trailing a CAGR of 7.5% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$11.4 Billion by the year 2027.

GERD Segment to Record 5.1% CAGR

In the global GERD segment, USA, Canada, Japan, China and Europe will drive the 5.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$5.1 Billion in the year 2020 will reach a projected size of US$7.1 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 5.5% CAGR through the analysis period.

What’s New for 2022?

• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies – Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and a Research Platform
• Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Gastrointestinal Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E)
• Impact of Covid-19 and a Looming Global Recession
• Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

• AbbVie, Inc.
• Alfa Wassermann, Inc.
• Allergan PLC
• Amgen, Inc.
• Anterogen Co., Ltd.
• Ardelyx, Inc.
• Astellas Pharma, Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Biogen, Inc.
• Celgene Corporation
• Cosmo Pharmaceuticals NV
• Drais Pharmaceuticals, Inc.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Enlivex Therapeutics ltd.
• F. Hoffmann-La Roche AG
• Ferring Pharmaceuticals, Inc.
• FF Pharma
• Galapagos NV
• Gilead Sciences, Inc.
• GlaxoSmithKline, Inc.
• Hutchison MediPharma Limited
• Immune Pharmaceuticals, Inc.
• InDex Pharmaceuticals Holding AB
• Ironwood Pharmaceuticals, Inc.
• Johnson & Johnson
• Kissei Pharmaceutical Co., Ltd.
• Kyowa Hakko Kirin Co., Ltd.
• Lexicon Pharmaceuticals, Inc.
• Lipid Therapeutics GmbH
• Meda AB
• Merck & Co., Inc.
• Mesoblast Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Mochida Pharmaceutical Co., Ltd.
• Morphotek, Inc.
• Neovacs S.A.
• Nestle SA
• Norgine BV
• Novartis AG
• Pfizer, Inc.
• Procter & Gamble Company, The
• Qu Biologics Inc.
• RedHill Biopharma Ltd.
• Sterna Biologicals GmbH & Co. KG
• Synthetic Biologics, Inc.
• Takeda Pharmaceutical Co., Ltd.
• TiGenix NV
• Tillotts Pharma AG
• TopiVert Ltd.
• UCB SA

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. REGIONAL MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/hhdnls

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900